SpinalCyte received a U.S. patent for its cartilage repair technology using an in vivo bioreactor.
Here are three things to know:
1. The patent, “Methods and Compositions For Repair Of Cartilage Using An In Vivo Bioreactor,” involves a bioreactor that is designed to acts as a delivery system to feed and grow fibroblasts and induce cellular differentiation.
2. The technology will also be subject to one or more growth factors, which may enhance cellular differentiation.
3. SpinalCyte’s portfolio now includes 33 U.S. and foreign patents and 43 patents pending. “Our patent portfolio uniquely positions us at the forefront of human dermal fibroblast cell therapy for spinal disc regeneration,” said SpinalCyte CEO Pete O’Heeron.
More articles on biologics:
Biologics in spine surgery holds great promise — Dr. Choll Kim shares insight into new field
InVivo Therapeutics concludes INSPIRE study: 5 things to know